Previous investigations in this laboratory have shown that normal human plasma rendered free from cellular elements, by Berkefeld filtration, is capable of reducing the coagulation time of the blood of patients with hemophilia both in vitro and in vivo (1). It has also been demonstrated that this coagulation activity of the plasma was associated with the globulin fraction of the plasma proteins (2, 3). The published data do not however identify the active material as a protein, nor do they differentiate it from fibrinogen and prothrombin, constituents of the globulin fraction which also play a role in blood coagulation. Indeed " globulin substance " as prepared by previous methods was known to contain both prothrombin and fibrinogen (2). The present communication concerns a study of the clot promoting activity of nornal human plasma, after the removal of prothrombin and fibrinogen.
Several authors (4, 5, 6) have described methods for the removal of prothrombin from blood plasma. These methods consist essentially of adsorption of this substance on the hydroxides of aluminum, calcium, or magnesium. Chew (7) has suggested recently that following filtration through Seitz filters (calcium magnesium aluminum iron silicate) a prothrombin free filtrate of plasma can be obtained.
By the use of the Quick et al. technique (8) it is possible to obtain a measure of the amount of prothrombin contained in preparations made from plasma.2 Table I 1The expenses of this investigation were defrayed in part by a gift to Harvard University from Smith, Kline, and French Laboratories, Philadelphia; and by a grant given in honor of Francis Weld Peabody by the Ella Sachs Plotz Foundation.
2All plasmas studied were derived from normal human 0.25 per cent citrated blood centrifuged 30 minutes at 2000 r.p.m., filtered through 2 thicknesses of Number 2 Whatman paper and then through a Berkefeld V filter.
shows the " prothrombin times " of certain of these preparations. It will be observed that while preparations with commercial aluminum hydroxide were quite inefficient the use of aluminum hydroxide C-gamma (9) gave preparations relatively free from prothrombin. The amount of prothrombin remaining depended upon the number of times the adsorption was repeated. More striking results were obtained however by passing Berkefeld filtrates of citrated normal human plasma 5 times through Seitz filters using fresh pads for each filtration. In addition to being prothrombin free these preparations had the advantage of being sterile. On the basis of these observations the Seitz filtration method was used routinely for the removal of prothrombin from plasma. Each batch of plasma treated in this manner was tested for prothrombin by the Quick technique and none was found. The presence of fibrinogen in the Seitz filtrate was demonstrated by the formation of a clot upon the addition of fresh serum as a source of thrombin. In one typical experiment one-tenth ml. of such serum clotted one-tenth ml. of the Seitz filtrate in 29 seconds.
Plasma was rendered free from fibrinogen by heat coagulation. The Berkefeld filtrate from fresh citrated normal human plasma was heated to 560 C. in the water bath. It was held at this temperature for 2 minutes and the copious precipitate containing the fibrinogen was removed by filtration. The absence of fibrinogen in the filtrate was demonstrated by the failure of clot formation when fresh serum acting as a source of thrombin was added. For the preparation of plasma free from both fibrinogen and prothrombin, the fibrinogen was removed by the above technique and the filtrate passed 5 times through Seitz filters to remove the prothrombin. When any of the preparations were to be stored they were dried by the lyophile method to avoid chemical change during desiccation.
EXPERIMENTAL
In vitro studies In vitro determinations of the clot promoting activity of plasma freed from prothrombin or both prothrombin and fibrinogen were made. Varying amounts of the preparations to be tested were added to 2 ml. of hemophilic blood, using the standard technique previously described (3). In some instances the results obtained were compared with the Berkefeld plasma from which the preparation was derived. Precise quantitative relationships were not possible since there was a loss of plasma to the filter pads and some evaporation occurred during the time required for Seitz filtration. The results however were sufficiently clear cut to permit conclusions to be drawn. A summary of the data from typical experiments is given in Table II. These data indicate that the greater part of the clot promoting activity of cellular free normal human plasma is not dependent on the presence of either fibrinogen or prothrombin, and remains in the filtrate from which these proteins are removed. The effect, in vivo, of a single injection of normal human plasma free from fibrinogen and prothrombin on the coagulation time of the blood of a patient uith hemophilia A patient with hemophilia was given a single intravenous injection of 50 ml. of normal human plasma free from fibrinogen and prothrombin.
The coagulation time of his blood fell from 110 minutes to 26 minutes 1 hour after the injection. This low level persisted for 6 hours after which it slowly returned to the pre-injection level reaching 100 minutes in 52 hours after the injection. These results are shown graphically in Figure 2 . A similar response to the administration of this material was obtained in a second patient with hemophilia. By a comparison of the data presented graphically in Figure 1 with the data previously published (1) on single intravenous injections of normal human citrated plasma into patients with hemophilia no essential difference can be discerned. Figures 1 and 2 Figure 3 . A comparison of these data with those previously published for multiple injections of unmodified normal human plasma (10) shows a close correspondence. The maintenance of a lowered coagulation time by repeated injections of unmodified plasma and preparations of plasma free from prothrombin and fibrinogen is in sharp contrast to the refractory phase reported as accompanying multiple injections of acid-precipitated " globulin substance " (3) .
DISCUSSION
In an earlier publication (2) it was pointed out that against a calcium-fibrinogen system *" globulin substance" behaved as prothrombin in the production of a fibrin clot. It was also shown that in this regard the preparations from the cellular free blood plasma of both normal persons and cases of hemophilia behaved in a similar manner. It was quite evident therefore that " globulin substance " contained prothrombin as defined by the clotting mechanism.
The " prothrombin time " as determined by the method of Quick et al. (8) of patients with hemophilia is normal. A fall of 20 per cent of the total amount of prothrombin may occur, however, without appreciable change in the "prothrombin time " (8) . For this reason a normal " prothrombin time " would not necessarily mean that the addition of more prothrombin could not force the coagulation mechanism toward clot formation, and hence decrease the coagulation time of the blood. It becomes necessary therefore to know whether the clot promoting activity of plasma described in earlier investigations published from this laboratory (1, 2) can exist in the absence of prothrombin.
The present observations seem to answer this question. Both in the test tube and following in- (12) . Since the presence of fibrinogen in "globulin substance " has been recorded (2), and since variations within " normal " limits in the fibrinogen content of the blood in hemophilia are known to occur it is again necessary to differentiate the clot promoting activity from this protein.
The data presented in this paper and also the experiences of Howell show that while fibrinogen is present in euglobulin (2) and in " globulin substance" prepared by acid precipitation, the removal of fibrinogen does not destroy the clot promoting activity of plasma. The in zitro observations of Howell and the data of the in vitro and in znvo observations of the present communication suggest, that so far as the patients studied are concerned, the coagulation defect in hemophilia does not lie in the prothrombin or fibrinogen fractions of the plasma proteins.
It is not implied, however, that deficiencies in fibrinogen and prothrombin may not modify the action of normal human plasma or derivatives of it on the blood of certain cases of hemophilia. Indeed Macfarlane's patient with congenital absence of fibrinogen and our own experiences with 2 atypical cases of hemophilia (13) would suggest that certain multiple deficiencies of factors controlling clotting may occur. Such interrelationships between the various substances present could be anticipated in a system of multiple components such as are concerned in the coagulation of the blood. The present report shows only that there exists in cellular-free normal human 
